Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA

~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~SAN DIEGO, CA / / September 24, 2026 / Ensysce Biosciences, Inc. NASDAQ:ENSC ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogen…